Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia

Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial

(2018) Jorge E. Cortes et al.   BLOOD

Role and mechanism of decitabine combined with tyrosine kinase inhibitors in advanced chronic myeloid leukemia cells

(2017) Li-Cai Jiang et al.   Oncology Letters

Dasatinib: A Review in Chronic Myeloid Leukaemia and Ph+ Acute Lymphoblastic Leukaemia

(2016) Gillian M. Keating   DRUGS

Accelerated Phase CML: Outcomes in Newly Diagnosed vs. Progression From Chronic Phase

(2016) Sudipto Mukherjee et al.   Current Hematologic Malignancy Reports

Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials

(2015) Koji Sasaki et al.   Lancet Haematology

Allogeneic hematopoietic SCT in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone in CML blast crisis

(2014) H Jiang et al.   BONE MARROW TRANSPLANTATION

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

(2013) M. Baccarani et al.   BLOOD

HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia

(2013) Paolo Strati et al.   CANCER

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

(2013) J.E. Cortes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase

(2011) Q. Jiang et al.   BLOOD

Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase

(2011) F J Giles et al.   LEUKEMIA

Imatinib combined with myeloablative allogeneic hematopoietic stem cell transplantation for advanced phases of chronic myeloid leukemia

(2011) Yi Luo et al.   LEUKEMIA RESEARCH

Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study

(2010) Giuseppe Saglio et al.   CANCER

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib

(2010) N. P. Shah et al.   HAEMATOLOGICA

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up

(2009) H. Kantarjian et al.   BLOOD

Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

(2009) Michele Baccarani et al.   JOURNAL OF CLINICAL ONCOLOGY

Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate

(2008) M. Brave et al.   CLINICAL CANCER RESEARCH

Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up

(2008) F. Palandri et al.   HAEMATOLOGICA